Upper Tract Urothelial Carcinoma (UTUC)Symptoms, Doctors, Treatments, Advances & More
Upper Tract Urothelial Carcinoma (UTUC) Overview
Learn About Upper Tract Urothelial Carcinoma (UTUC)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Memorial Sloan Kettering Cancer Center
Guido Dalbagni is a Urologist practicing medicine in New York, New York. Dr. Dalbagni is rated as an Elite provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). He is also highly rated in 21 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Upper Tract Urothelial Carcinoma (UTUC), Cystectomy, and Nephrectomy. Dr. Dalbagni is currently accepting new patients.
UC San Diego
Ithaar Derweesh is a Urologist practicing medicine in San Diego, California. Dr. Derweesh is rated as an Elite provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Upper Tract Urothelial Carcinoma (UTUC), Urothelial Cancer, Nephrectomy, and Reconstructive Urology Surgery.
Henry Ford Medical Center-Lakeside
Firas Abdollah is a Urologist practicing medicine in Sterling Heights, Michigan. Dr. Abdollah is rated as an Elite provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Upper Tract Urothelial Carcinoma (UTUC), Urothelial Cancer, Prostatectomy, and Nephrectomy. Dr. Abdollah is currently accepting new patients.
Summary: A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma
Summary: The primary purpose of this trial is to evaluate the safety \& tolerability of Nadofaragene Firadenovec in subjects with LG-UTUC. To help with this evaluation, a safety lead-in period will be conducted for the first 6 subjects. Complete response is at 3 or 6 months defined as absence of any UTUC in the renal pelvis.